Thomas P. Witelski, Ph.D. (NY I ’91), has been named as the Associate Director of the Statistical and Applied Mathematical Sciences Institute (SAMSI), beginning July 1. Currently, Dr. Witelski is a professor of mathematics at Duke University “specializing in nonlinear partial differential equations and fluid dynamics.”
Before working at Duke, he was an NSF Postdoctoral Fellow and an applied mathematics instructor at MIT. Dr. Witelski is also the co-Editor-in-Chief of the Journal of Engineering Mathematics and the division editor of the Journal of Mathematical Analysis and Applications. He also serves on the editorial board for the European Journal of Applied Mathematics, Discrete and Continuous Dynamical Series B. For more information read the news announcement
In conjunction with the soon to be published Summer issue of The Bent, Tau Beta Pi has posted the Fellowship Reports of the 80th class of TBP Fellows. The reports are the only specific obligation to the Association for Fellows. Of the 40 Fellows, 38 submitted their reports for publication. One Fellow was unable to be reached and the other deferred her Fellowship and will submit her report next year. Click here for more information on the Tau Beta Pi Fellowship Program.
The National Cancer Institute at the National Institutes of Health awarded a group led by Richard J. Price, Ph.D. (NY P ’90), a five-year grant to test ideas related to treating brain cancer. Dr. Price and his colleagues, at Johns Hopkins University, have developed a technique designed to open the blood-brain barrier at targeted locations just far enough to allow the passage of drug-bearing nanoparticles. Read more from Medical Xpress
Dr. Price is a professor of biomedical engineering at the University of Virginia specializing in the management of microbubbles. “We’re taking an accepted diagnostic tool and using it therapeutically,” Dr. Price said. “Two formulations have FDA approval. We joined forces with John Hopkins because we each had a technology that addresses one of the two big physical barriers to drug delivery in the brain. We decided to put the two technologies together and see if that combination can actually produce efficacy.”